Vanguard Global Advisers
PBYI icon

Vanguard Global Advisers’s Puma Biotechnology PBYI Stock Holding History

Vanguard Global Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Buy
46,267
+17,094
+59% +$125K ﹤0.01% 2231
2026
Q1 		$186K Buy
+29,173
New +$188K ﹤0.01% 2474

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's PBYI Position: Q2 2026 in Review

Vanguard Global Advisers increased its Puma Biotechnology (PBYI) stake by 59% in Q2 2026, buying an estimated $125K and bringing the position to 46,267 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2231.

Vanguard Global Advisers first reported a position in PBYI in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Vanguard Global Advisers held 46,267 shares of Puma Biotechnology worth $375K as of Q2 2026.
  • Vanguard Global Advisers bought 17,094 Puma Biotechnology shares in Q2 2026, an estimated $125K.
  • Puma Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2231 holding.
  • Vanguard Global Advisers first reported a position in Puma Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.